Detalhe da pesquisa
1.
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
N Engl J Med
; 386(9): 847-860, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139271
2.
Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Clin Infect Dis
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38657084
3.
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
N Engl J Med
; 384(23): 2187-2201, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882225
4.
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
N Engl J Med
; 384(19): 1824-1835, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33440088
5.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
PLoS Med
; 19(1): e1003865, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015777
6.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis
; 223(7): 1171-1182, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31821493
7.
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
PLoS Med
; 18(10): e1003813, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34714820
8.
Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
J Infect Dis
; 220(1): 46-56, 2019 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796818
9.
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
JAMA
; 315(15): 1610-23, 2016 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092831
10.
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Vaccines (Basel)
; 12(5)2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38793748
11.
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Clin Pharmacol Ther
; 113(2): 380-389, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36377532
12.
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
Vaccine
; 41(37): 5351-5359, 2023 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517912
13.
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year.
JAMA
; 317(10): 1075-1077, 2017 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28291882
14.
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age.
Hum Vaccin Immunother
; 18(5): 2044255, 2022 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35344464
15.
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
PLoS One
; 17(10): e0274906, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36197845
16.
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
Vaccine
; 40(32): 4403-4411, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35667914
17.
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen.
NPJ Vaccines
; 6(1): 157, 2021 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930928
18.
Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
Hum Vaccin Immunother
; 17(5): 1366-1373, 2021 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33175637
19.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 39(22): 3081-3101, 2021 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676782
20.
Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda.
Glob Health Action
; 13(1): 1829829, 2020 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-33073737